# Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

> **NCT06667973** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 80 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- FLT3 Gene Mutation
- Adult AML
- Diagnosis

## Interventions

- **DRUG:** Gilteritinib

## Key facts

- **NCT ID:** NCT06667973
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2028-08
- **Final completion:** 2030-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06667973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06667973, "Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06667973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*